1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Enzo Biochem, Inc.

Enzo Biochem, Inc.

ENZ
Enzo Biochem, Inc.US flagNew York Stock Exchange
0.31
USD
-0.02
- -
16.44MMarket Cap
Enzo Biochem, Inc.
ENZ
(New York Stock Exchange)

Recent

price

0.31

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
2.39
2.55
2.66
2.66
2.37
2.25
2.15
2.23
2.27
2.15
1.71
1.59
2.44
0.67
0.63
0.63
0.56
Revenue per Share
-0.63
-0.59
-0.34
-1.01
-0.46
-0.23
-0.05
0.98
-0.05
-0.22
0.05
-0.6
0.16
-0.38
0.41
-0.51
-0.41
Basic EPS, GAAP
-0.31
-0.35
-0.22
-0.15
-0.25
-0.04
-0.08
1.15
- -
-0.06
0.1
-0.36
0.01
-0.34
-0.75
-0.52
-0.29
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-4.78
-5.3
-5.59
-6.54
-6.87
-6.62
-6.27
-5.18
-5.21
-5.36
-5.26
-5.82
-5.6
-5.93
-5.45
-5.77
-5.76
Book Value per Share
1.86
1.36
1.08
0.77
0.42
0.5
0.64
1.68
1.69
1.53
1.64
1.06
1.26
0.97
1.6
1.1
0.9
Tangible Book Value per Share
38
38
38
39
40
43
45
46
46
47
47
48
48
49
49
51
52
Basic Weighted Avg Shares
90
97
102
103
94
96
98
103
105
101
81
76
118
33
31
32
29
Sales/Revenue/Turnover
-21.45
-22.72
-12.67
-15.46
-20.25
-13.84
-12.98
-10.12
-3
-12.04
-33.5
-39.95
0.59
-53.69
-79.64
-38.75
-34.14
Operating Margin (%)
3
4
4
4
5
4
4
4
4
3
3
3
3
3
3
1
1
Depreciation Expense
-24
-22
-13
-39
-18
-10
-2
45
-3
-10
2
-29
8
-18
20
-26
-21
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
2.32
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-26.31
-22.9
-12.7
-38.09
-19.46
-10.4
-2.34
44.06
-2.38
-10.22
3.07
-37.52
6.69
-55.94
65.32
-81.73
-73.25
Profit Margin (%)
61
42
34
21
9
16
23
71
71
63
65
36
45
30
58
45
35
Working Capital
- -
- -
- -
- -
1
1
1
1
1
- -
4
21
19
8
3
3
2
LT Debt
117
97
89
49
34
37
43
90
89
81
86
58
69
54
78
56
47
Total Equity
- -
- -
- -
- -
- -
- -
- -
-15.29
- -
- -
-32.1
- -
0.76
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
-17.51
- -
- -
-1
- -
-3.2
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jul'24
Oct'25
Jan'25
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
52
52
52
Market Capitalization
53
54
31

Working Capital

FRC

•

in mil. unless spec.
Jul'24
Oct'25
Jan'25
Total Current Assets
70
60
52
Cash, Cash Equivalents & STI
52
48
40
Accounts Receivable, Net
4
4
4
Inventories
7
6
6
Total Current Liabilities
25
23
17
Payables & Accruals
6
12
5
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.24%
-3.93%
-28.49%
Free Cash Flow
-541.24%
-970.52%
-28.98%
Net Income, GAAP
-422.14%
-429%
-228.54%
Sales/Revenue/Turnover
-4.01%
-5.17%
2.72%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
7
8
7
-20
31
2024
8
9
8
8
32
2025
6
7
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.22
-0.23
-0.31
- -
0.41
2024
-0.13
-0.06
-0.06
- -
-0.51
2025
-0.06
-0.03
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
ACS Global, Inc. (AMCY)
Human Metabolome Technologies, Inc. (6090.T)
IDEXX Laboratories, Inc. (0J8P.L)
Cryosite Limited (CTE.AX)
Medivolve Inc. (4NC.F)
Psychemedics Corporation (PMD)
Business
Enzo Biochem, Inc. (ENZ) is a life sciences company specializing in labeling and detection technologies for genomic, protein, cell, and tissue analysis. The company offers a comprehensive portfolio of over 6,000 proprietary products, including antibodies, genomic probes, immunoassays, biochemicals, proteins, dyes, and labeling kits; these tools support applications in translational research, drug discovery, drug development, cell biology, genomics, immunohistochemistry, small molecule chemistry, and nucleic acid detection. Enzo Biochem also provides custom manufacturing services, GMP services, assay and validation testing, and licensing of its technologies, serving academic researchers, biotechnology firms, pharmaceutical companies, and diagnostic manufacturers worldwide through offices in the United States, Switzerland, Germany, France, the United Kingdom, and Benelux regions. Founded in 1976 and headquartered in Farmingdale, New York, the company operates primarily through its Enzo Life Sciences division, leveraging over 500 patents, in-house U.S. manufacturing, and a workforce with more than 25% PhD scientists to deliver rigorously validated, high-sensitivity products cited in over 175,000 publications. In June 2025, Enzo Biochem entered into a definitive merger agreement to be acquired by Battery Ventures for approximately $37 million, or $0.70 per share in cash, following a strategic review by a special committee of its Board of Directors; the take-private transaction was completed in August 2025, transitioning the company to private ownership under Battery Ventures to support accelerated innovation, R&D investment, market expansion, and targeted acquisitions. Concurrent with the acquisition, veteran life sciences executive Jason Apter joined as Group CEO, backed by Battery partners on the board including Justin Rosner, Jesse Feldman, and Alan Hirzel. In fiscal year 2025, the company launched approximately 100 new products per quarter amid life sciences sector challenges, reported sequential revenue improvements to $7.3 million in Q2, and maintained focus on cost containment and product lifecycle maintenance.

Company News

APIChat

  • globenewswire.com

    Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction

  • globenewswire.com

    Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results

  • globenewswire.com

    Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction

  • zacks.com

    The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment

  • globenewswire.com

    Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX

  • globenewswire.com

    Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results

  • globenewswire.com

    Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules

  • zacks.com

    ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges

  • globenewswire.com

    Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update

  • zacks.com

    ENZ Stock Up Following FY24 Earnings Uptick, Gross Margin Expands

  • globenewswire.com

    Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend

  • reuters.com

    Enzo Biochem to pay $4.5 mln for failing to safeguard patient data

  • seekingalpha.com

    Enzo Biochem: Is This Time Finally Different?

  • zacks.com

    Zacks Initiates Coverage of Enzo Biochem With Neutral Recommendation

  • zacks.com

    Enzo Biochem (ENZ) Q3 Earnings Improve Y/Y, Gross Margin Up

  • globenewswire.com

    Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update

  • globenewswire.com

    Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update

  • globenewswire.com

    Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments

  • globenewswire.com

    ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE

  • globenewswire.com

    Steven J. Pully Appointed to Enzo Biochem's Board of Directors